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Abstract
The combination of neonatal hyperammonemia, lactic acidosis, ketonuria, and
hypoglycemia is pathognomonic for carbonic anhydrase VA (CA-VA) deficiency. We present two cases of this rare inborn error of metabolism. Both
newborns with South Asian ancestry presented with a metabolic decompensation characterized by hyperammonemia, lactic acidosis and ketonuria; one also
had hypoglycemia. Standard metabolic investigations (plasma amino acids,
acylcarnitine profile, and urine organic acids) were not indicative of a specific
organic aciduria or fatty acid oxidation defect but had some overlapping features with a urea cycle disorder (elevated glutamine, orotic acid, and low arginine). Hyperammonemia was treated initially with nitrogen scavenger therapy
and carglumic acid. One patient required hemodialysis. Both have had a favorable long-term prognosis after their initial metabolic decompensation. Genetic
testing confirmed the diagnosis of carbonic anhydrase VA (CA-VA) deficiency
due to biallelic pathogenic variants in CA5A. These cases are in line with
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15 cases previously described in the literature, making the phenotypic presentation pathognomonic for this ultrarare (potentially underdiagnosed) inborn
error of metabolism with a good prognosis.
KEYWORDS
encephalopathy, ketonuria, lactic acidosis, metabolic acidosis, neonatal hyperammonemia

1 | INTRODUCTION
Carbonic anhydrases catalyze the reversible hydration of
carbon dioxide and produce bicarbonate. Human carbonic
anhydrase VA (CA-VA) is a mitochondrial enzyme present
in the liver, kidney, and skeletal muscle. CA-VA supplies
bicarbonate as a substrate of four mitochondrial enzymes:
carbamoyl phosphate synthetase, 1,3-methylcrotonyl-CoA
carboxylase 1, propionyl-CoA carboxylase, and pyruvate
carboxylase (Figure 1). Biallelic variants in CA5A cause a
rare autosomal recessive inborn error of metabolism called
CA-VA deficiency (OMIM 615751). Patients with this condition have metabolic crises, which are characterized by
encephalopathy, hyperammonemia, lactic acidosis,
ketonuria, and hypoglycemia. The first report of CA-VA
deficiency identified four patients from two unrelated families.1 In 2016, a larger case series of 10 patients was
reported.2 Subsequent to these initial reports, only one further case has been reported in the literature.3 We describe

here two cases of CA-VA deficiency who have a similar
presentation to the 15 cases previously reported in the literature. Our cases both presented with metabolic acidosis,
high lactate and hyperammonemia and responded well to
standard therapy with a good prognosis following the initial
metabolic decompensation.

2 | CASE 1
The first case is a male infant who was born to nonconsanguineous parents originally from Punjab, India.
The baby was delivered at term by caesarian section after
a failed trial of induction of labor and presence of maternal fever. He was born with APGAR scores 91 and 95 and
his birth weight was 4250 g (87th centile).
At day 1 of life, he was noted to be jittery and had two
episodes of hypoglycemia recorded at 1.7 and 1.9 mmol/L
(>2.4 mmol/L). These episodes corrected promptly with

F I G U R E 1 The intermediary metabolism of carbonic anhydrase (CA-VA). Carbonic anhydrases catalyze the reversible hydration of
carbon dioxide and produce bicarbonate. Human carbonic anhydrase VA (CA-VA) is a mitochondrial enzyme present in the liver, kidney,
and skeletal muscle. CA-VA supplies bicarbonate as a substrate of four mitochondrial enzymes: carbamoyl phosphate synthetase 1 (CPS1),
3-methylcrotonyl-CoA carboxylase (3MCC), propionyl-CoA carboxylase (PCC), and pyruvate carboxylase (PC)
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feeds. He became very irritable the following day and
developed tachypnea and tachycardia. Blood gas analysis
showed pH of 7.57 (7.35-7.45), PCO2 < 18 mmHg (35-45),
HCO3− of 13.2 mmol/L (22-28) with base excess of −5.1
(−2 to +3) indicating mixed metabolic acidosis and respiratory alkalosis. Blood lactate was 7.5 mmol/L (0.9-2.4)

TABLE 1

and ammonia was 254 μmol/L (15-55). He was started on
intravenous fluids, antibiotics (ampicillin and gentamycin), sedated, intubated, and transferred to a tertiary
care center with a suspicion of an inborn error of metabolism. Metabolic investigations, as shown in Table 1, were
not diagnostic of a urea cycle disorder or organic aciduria.

Summary of initial metabolic investigations in the two cases

Metabolic investigation

Case 1

Case 2

Newborn screening

Normal

Normal

Plasma amino acids, carnitine (μmol/L)

Day 2 of life:
Elevated alanine 788 (70-387)
Elevated glutamine 949 (66-620)
Low arginine 16 (22-78)
Normal citrulline 17 (10-38)
Low free carnitine 4 (10-30)
Normal total carnitine 27 (15-45)

Day 5 of life:
Elevated alanine 1130 (325-425)
Normal arginine 39 (30-70)
Normal citrulline 15 (0-26)
Low free carnitine 3.5 (12-60)
Low total carnitine 9.5 (23-84)
Day 7 of life:
High free carnitine 494 (12-60)
High total carnitine 526 (23-84)

Urine orotic acid (mmol/mol creatinine)

Slightly elevated 6 (0.0-5.6)

Normal 1.9 (1.4-5.3)

Urine organic acids

Day 2 of life:
Lactic acid (large)
Ketones (large)
Dicarboxylic acids(large)
Pyruvic acid (large)
3-Hydroxyisovaleric acid (large)
2-Hydroxy-3-methylsuccinic acid (large)
3-Methylcrotonylglycine (small)
Tiglylglycine (small)
2-Ethyl-3-hydroxypropionic acid (small)
Palmitic acid (small)
Days 3, 17, 51 of life:
Unremarkable

Day 5 of life:
Lactic acid
Ketones
Dicarboxylic acids
Liver metabolites (large)
2-Hydroxyisovaleric acid (small)
3-Hydroxyisovaleric acid (small)
3-Hydroxy-3-methylglutaric acid (small)
2-Ethyl-3-hydroxypropionic acid (small)

Acylcarnitine profile (μmol/L)

Day 2 of life:
C4-OH 0.61 (<0.33)
C6-OH 0.18 (<0.04)
Day 51 of life:
C2 39.8 (7.6-27.8)
C3 0.97 (<0.65)
C6-OH 1.23 (>0.16)

Day 5 of life:
Initially low

Allele 1: c.721G>A, p.(Glu241Lys)
Allele 2: c.619-?_774+?del

Allele 1: c.721G>A, p.(Glu241Lys)
Allele 2: c.721G>A, p.(Glu241Lys)

CA5A sequencing

C0 11.6
C2 7.35
C3 0.82
C4 0.06
C8:1 0.08
C8 0.08
C10:1 0.02
C5DC 0.05
C12:1 0.03
C12 0.07
C120H 0.02
C14:2 0.09
C14:1 0.03
C14 0.16

Day 7 of life:
After carnitine
Supplement
Large multiple
Elevations noted
488 (18-47)
33.2 (4.6-35.4)
2.53 (<1.08)
1.31 (<0.68)
1.26 (<0.68)
0.64 (<0.30)
0.68 (<0.29)
0.38 (<0.14)
0.27 (<0.19)
0.21 (<0.19)
0.22 (<0.05)
0.27 (<0.09)
0.23 (<0.21)
0.10 (<0.11)
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The metabolites found in the urine organic acids raised
the consideration of multiple carboxylase deficiency,
though biotinidase deficiency was ruled out with enzymatic testing.
At 56 hours of age, the hyperammonemia was initially managed with intravenous nitrogen scavengers
(sodium benzoate/sodium phenylacetate), L-arginine,
dextrose and lipids. After a slight initial decline, his
ammonia level increased to 361 μmol/L within 4 hours
and he became nonresponsive. Hemodialysis was initiated which reduced the ammonia level to 64 μmol/L.
Post hemodialysis, he was given carglumic acid 100 mg
OD and managed with biotin 5 mg OD until biotinidase
deficiency was ruled out.
A brain MRI at 4 days of life was unremarkable. The
blood ammonia level remained <100 μmol/L and the
baby was discharged at 9 days of life with no dietary
restrictions. Subsequent ammonia levels, growth and
development have remained normal. He is currently
19 months old, growing well, and meeting all developmental milestones without receiving medications. The
family has been provided with a medical care plan in
event of any decompensation. At 45d of age, a
hyperammonemia targeted gene panel identified two
likely pathogenic heterozygous variants in CA5A:
c.721G>A, p.(Glu241Lys), and c.619-?_774+?del. The two
variants were confirmed by Sanger sequencing and
qPCR, respectively. Parental follow-up testing showed
the variants were in trans.

3 | C AS E 2
The second case is a 9-year-old boy who was born at term
to consanguineous parents (first cousins) of Sri-Lankan
descent. He was delivered at term by spontaneous vaginal
delivery. He was born with APGAR scores 81 and 95 and
his birth weight was 3065 g (25th centile). The pregnancy
was complicated only by gestational diabetes.
After initial discharge home on day 2, he was
readmitted to the neonatal unit at 72 hours of age due to
poor feeding, jaundice, tachycardia, tachypnoea, and
lethargy. Laboratory investigations revealed a significant
metabolic acidosis pH of 7.16 (7.35-7.45), PCO2 mmHg
13 (35-45), HCO3− of 5 mmol/L (22-28) with base excess
of −21 (−2 to +3), and an anion gap of 33 (<15). He also
had an elevated lactate at 6.6 mmol/L (0.9-2.4) and
ammonia at 363 μmol/L (15-55). He was resuscitated
with fluid boluses, given a bicarbonate correction, started
on antibiotics and transferred to a tertiary center intensive care unit for ongoing management. His initial metabolic investigations are shown in Table 1. The results
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were not thought to be diagnostic of a particular condition, though, multiple carboxylase deficiency, pyruvate
carboxylase deficiency and mitochondrial disorder were
high in the differential diagnosis. His initial plasma carnitine levels were below the normal range (total carnitine 9.5 μmol/L [23-84] and free carnitine 3.5 μmol/L
[12-60]). A repeat acylcarnitine profile, after intravenous
carnitine supplementation, showed multiple elevations.
That along with the presence of multicystic kidneys led
to the suspicion of a potential diagnosis of multiple acylCoA dehydrogenase deficiency (glutaric aciduria type
2, GA2). However, sequencing of ETFA, ETFB, and
ETFDH genes was negative and fibroblast analysis revealed a normal palmitate oxidation acylcarnitine profile
(WJ Rhead, Wisconsin, USA). Mitochondrial fibroblast
studies showed normal results for pyruvate dehydrogenase, pyruvate carboxylase, 2-oxoglutarate dehydrogenase, cytochrome c oxidase, succinate cytochrome c
reductase, mitochondrial NADH cytochrome c reductase,
oligomycin sensitive ATPase, citrate synthase, and
cellular lactate/pyruvate ratio (B Robinson, Toronto,
Canada). We therefore cannot explain the multiple
elevations on the acylcarnitine profile, which may
represent the consequence of intravenous carnitine
supplementation.
Hyperammonaemia was managed with Ammonul
(sodium benzoate, sodium phenylacetate), L-carnitine,
carglumic acid, L-arginine, and dextrose. His ammonia
returned to normal levels within 24 hours and he did
not require hemodialysis. He was discharged on oral carnitine supplementation that was discontinued when he
was 3 months old, and riboflavin 100 mg per day that
was later increased to 150 mg per day and eventually
discontinued at 3½ years of age. He underwent an MRI
of the brain, which showed laminar subdural hematomas in the parietooccipital regions, posterior fossa, and
posterior falx. There was also some nonspecific
hyperintensity of the deep white matter regions in the
frontal, parietal, and occipital lobes. He also had an
abdominal ultrasound that showed small dysplastic and
multicystic kidneys bilaterally.
Currently he is 9 years-old and doing well clinically
with no developmental concerns. He was issued with an
emergency care plan to perform a blood gas, lactate, urinalysis for ketones, CK, glucose, transaminase, urea, creatinine, and electrolytes during any acute illness.
However, he has not had any further decompensations.
He eventually underwent targeted genetic sequencing of
CA5A, which showed he was homozygous for the likely
pathogenic variant c.721G>A, p.(Glu241Lys). His parents
were confirmed to be heterozygous carriers for the
variant.
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4 | DISCUSSION
Neonatal hyperammonemia with or without lactic acidosis has a wide differential diagnosis and often initial evaluation and management is targeted to a potential urea
cycle disorder or organic aciduria. CA-VA deficiency is
an extremely rare, or perhaps underdiagnosed cause of
hyperammonemia, which has the potential to lead to
diagnostic confusion with other inborn errors of metabolism. The differential diagnosis of CA-VA deficiency
includes transient hyperammonemia of the newborn,
pyruvate carboxylase deficiency, multiple carboxylase
deficiency, CPS1 deficiency, and NAGS deficiency. The
results of the metabolic investigations allow the differentiation of CA-VA deficiency from above disorders. In
transient hyperammonemia of the newborn, there is isolated hyperammonemia with all other metabolites often
being normal (including glutamine and alanine). In pyruvate carboxylase deficiency there is an elevated citrulline
and lysine, and proximal early infantile onset urea cycle
defects typically have normal lactate and ketone levels
and low plasma citrulline concentrations. In our patients,
other diagnoses that were initially considered included
multiple carboxylase deficiencies, multiple acyl-CoA
dehydrogenase deficiency, and mitochondrial disorders.
The overlap with metabolites identified in multiple carboxylase deficiency (ie, holocarboxylase synthase deficiency or biotinidase deficiency) occurs as biotin is an
obligatory cofactor for the three carboxylases that also
require bicarbonate as a substrate. However, multiple
carboxylase deficiency does not often present with
hyperammonemia, and biotinidase deficiency was ruled
out enzymatically in patient 1. Multiple acyl-CoA dehydrogenase deficiency was considered because patient
2 had multicystic kidneys and a suggestive acylcarnitine
profile after carnitine supplementation.
The two cases we describe here showcase the major
presentation of CA-VA deficiency that has been described
previously.1,2 The age of onset for both our cases was in
the first few days of life. Previous reports have indicated an
age of onset of between 2 days to 4 years but 67% of
patients presented before day 5 of life. This early presentation indicates that newborn screening results may not be
available at the time of presentation. Case 1 and case 2
were negative in the newborn screening test. All CA-VA
deficiency patients have presented with hyperammonemia
(238-1150 μmol/L), elevated lactate (4.8-15 mmol/L) and
ketonuria, and most had hypoglycemia as well. Our cases
also had these essential features of the initial presentation.
Metabolic acidosis is not a universal feature but was present in both our cases. In case 1, the metabolic profile was
consistent with a possible urea cycle disorder, but this was
not shown in case 2. The metabolites identified in the urine
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organic acid analysis of our cases are like those described
in the 15 published CA-VA deficient patients.1,2 The main
treatment is carglumic acid (Carbaglu), which is an analogue of N-acetylglutamate (NAG) approved for treating
acute hyperammonemia in NAGS deficiency.4,5 Propionyl
CoA carboxylase cannot function efficiently because of the
HCO3− deficiency caused by CA-VA deficiency and propionyl CoA is a potent inhibitor of NAGS. Carbamoyl phosphate synthetase CPS1 does not function because of the
NAG and HCO3− deficiency. Carglumic acid has been
shown to be beneficial in treating hyperammonemia in
53% of the published cases of CA-VA deficiency.2 It was
used as a therapy in both of our cases; however, case
1 needed hemodialysis. In our centers, carglumic acid is
used as standard therapy during an unexplained first
hyperammonemic episode. Due to the initial diagnostic
uncertainty, other therapies more often used in other causes of hyperammonemia (nitrogen scavengers, arginine,
lipids, and carnitine) were used initially in both cases. We
also report a good neurodevelopmental outcome in our
patients, which is consistent with 86% of the previously
reported cohort. Ammonia levels, in both patients, have
remained normal without nitrogen scavenger treatment,
even during infections later in life. There have been no dietary modifications in either patient as they have been metabolically stable. More than 65% of patients with CA-VA
deficiency experienced a similar single neonatal
hyperammonemia crisis without recurrence.2 It has been
hypothesized that CA-VA has an isoform, CA-VB, whose
expression is upregulated in the absence of functional CAVA later in life.2 There has been a recent single case report
of fatality associated with CA-VA deficiency at age
18 months, thus, it is important to monitor and measure
ammonia promptly in events of any illnesses.3
Our patients were both from the Indian subcontinent
as were 71% of the patients with CA-VA deficiency previously identified. This propensity to identify cases from
the same ethnic background raises the possibility of a
founder effect. The gene CA5A is 50Kb long with seven
exons and six introns. Most pathogenic variants occur in
exons 4 and 6. The genetic variants in our cases have
both been previously described. The c.721G>A, p.
(Glu241Lys) (rs563971993) (NM_001739.2) variant was
present in both cases and falls within exon 6. It has an
overall population minor allele frequency of 3.09e−4 and
has not been observed as homozygous before. This variant is observed in 0.27% of alleles in individuals from a
south Asian background in the gnomAD database.6 The
Glu241Lys change is a nonconservative amino acid substitution, which is likely to impact secondary protein
structure as these residues differ in polarity, charge, size
and/or other properties. This variant is reported as likely
pathogenic variant in ClinVar database. The c.619–?_774
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+?deletion removes exon 6 and is similar to pathogenic
deletions identified in ClinVar that have been reported in
patients having Indian subcontinent ancestry.2
In summary, we present two cases which add to the
limited previous reports of CA-VA deficiency. CA-VA deficiency is a recently described ultrarare inborn error of
metabolism with most patients being from the Indian subcontinent. It presents early in life with a hyperammonemia
crisis accompanied by respiratory alkalosis/metabolic acidosis, lactic acidosis, ketonuria, and hypoglycemia. The
outcome is often favorable with normal neurodevelopment
and no further crises following prompt and temporary
treatment of hyperammonemia with carglumic acid.
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